BEAM Alliance News

Combioxin Announces an Oral Presentation on CAL02 clinical results at ESICM 2018
Combioxin SA
— October 2018 — 13 views

AntibioTx announces company name change to UNION therapeutics
UNION therapeutics A/S
— October 2018 — 4 views

Motif Bio Presents New Iclaprim Data at IDWeek
Motif Bio plc
— October 2018 — 35 views

Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences
Motif Bio plc
— September 2018 — 35 views

Novo Holdings invests CHF 6.8 Million in Polyphor to accelerate the development of novel antibiotics against multi-drug resistant Gram-negative pathogens
Polyphor Ltd
— September 2018 — 45 views

Motif Bio Presents Iclaprim Data at ESCMID/ASM Conference
Motif Bio plc
— September 2018 — 47 views

Viruses Against Bacteria: Development of Novel Therapeutics Boosted With Millions of Euros
PhagoMed Biopharma GmbH
— August 2018 — 55 views

Madam Therapeutics closes first financing round to develop novel antibiotics against drug resistant bacteria
Madam Therapeutics BV
— August 2018 — 53 views

Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections
Motif Bio plc
— August 2018 — 43 views

Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037
Motif Bio plc
— August 2018 — 50 views

Destiny Pharma announces research collaboration with Aston University to investigate new XF-platform drug candidates
Destiny Pharma plc
— July 2018 — 113 views

ANTABIO Completes € 12.5M Series A
ANTABIO S.A.S
— July 2018 — 108 views

Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
Summit Therapeutics plc
— July 2018 — 105 views

Deinove enters into collaboration with bioMérieux to discover new antibiotics
DEINOBIOTICS/DEINOVE
— June 2018 — 141 views

DEINOVE: SUCCESSFUL CAPITAL INCREASE OF € 8.5 MILLION
DEINOBIOTICS/DEINOVE
— June 2018 — 166 views

Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program
Arsanis Biosciences GmbH
— June 2018 — 93 views

Destiny Pharma notes FDA statement on their focus to enable new approaches to fight AMR
Destiny Pharma plc
— June 2018 — 94 views

Motif Bio Submits NDA for Iclaprim
Motif Bio plc
— June 2018 — 123 views

ASM Microbe 2018: Nosopharm to present new first-inclass clinical candidate to tackle interobacteriaceae infections
NOSOPHARM
— June 2018 — 101 views

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed at the House of Representatives.
BEAM Alliance, BEAM Alliance
— June 2018 — 158 views

Nosopharm renews its partnership with Inra
NOSOPHARM
— May 2018 — 132 views

Gedea Biotech has received 1 MSEK for clinical study for CE mark of new product
Gedea Biotech AB
— May 2018 — 127 views

DEINOVE integrates into its pipeline a candidate antibiotic ready to enter phase IIand intends to respond to a major health emergency
DEINOBIOTICS/DEINOVE
— May 2018 — 119 views

MOTIF BIO TO PRESENT ICLAPRIM DATA AT ASM MICROBE 2018
Motif Bio plc
— May 2018 — 120 views

Stay updated :

Participate on our social stream.

Archives

Tags